Peripheral neuropathy and antiretroviral drugs

Publisher Website
Google Scholar
Abstract
Patients treated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) develop a varying degree of myopathy or neuropathy after long‐term therapy. Zidovudine (AZT) causes myopathy; zalcitabine (ddC), didanosine (ddI) and lamuvidine (3TC) cause neuropathy; stavudine (d4T) and fialuridine (FIAU) cause neuropathy or myopathy and lactic acidosis. The tissue distribution of phosphorylases responsible for phosphorylation of NRTIs relates to their selective tissue toxicity. The myopathy is characterized by muscle wasting, myalgia, fatigue, weakness and elevation of CK. The neuropathy is painful, sensory and axonal. In vitro, NRTIs inhibit the gamma‐DNA polymerase, responsible for replication of mtDNA, and cause mtDNA dysfunction. In vivo, patients treated with AZT, the best studied NRTI, develop a mitochondrial myopathy with mtDNA depletion, deficiency of COX (complex IV), intracellular fat accumulation, high lactate production and marked phosphocreatine depletion, as determined with in vivo MRS spectroscopy, due to impaired oxidative phosphorylation. Animals or cultured cells treated with NRTIs develop neuropathy, myopathy, or cell destruction with similar changes in the mitochondria. There is evidence that the NRTI‐related neuropathy is also due to mitochondrial toxicity. The NRTIs (AZT, ddC, ddI, d4T, 3TC) contain azido groups that compete with natural thymidine triphosphate as substrates of DNA pol‐gamma and terminate mtDNA synthesis. In contrast, FIAU that contains 3′‐OH groups serves as an alternate substrate for thymidine triphosphate with DNA pol‐gamma and is incorporated into the DNA causing permanent mtDNA dysfunction. The NRTI‐induced mitochondrial dysfunction has an influence on the clinical application of these agents, especially at high doses and when combined. They have produced in humans a new category of acquired mitochondrial toxins that cause clinical manifestations resembling the genetic mitochondrial disorders.